Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Increased number and function of FoxP3 regulatory T cells during experimental arthritis.

Monte K, Wilson C, Shih FF.

Arthritis Rheum. 2008 Dec;58(12):3730-41. doi: 10.1002/art.24048.

2.

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8. doi: 10.1073/pnas.0806173105. Epub 2008 Oct 24.

3.

Monocyte chemoattractant protein-1: a key mediator in inflammatory processes.

Melgarejo E, Medina MA, Sánchez-Jiménez F, Urdiales JL.

Int J Biochem Cell Biol. 2009 May;41(5):998-1001. doi: 10.1016/j.biocel.2008.07.018. Epub 2008 Aug 8. Review.

PMID:
18761421
4.

Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation.

Xu H, Oriss TB, Fei M, Henry AC, Melgert BN, Chen L, Mellor AL, Munn DH, Irvin CG, Ray P, Ray A.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6690-5. doi: 10.1073/pnas.0708809105. Epub 2008 Apr 24.

5.

IL-10: the master regulator of immunity to infection.

Couper KN, Blount DG, Riley EM.

J Immunol. 2008 May 1;180(9):5771-7. Review.

6.

CD4+CD25+ regulatory T cells selectively diminish systemic autoreactivity in arthritic K/BxN mice.

Kang SM, Jang E, Paik DJ, Jang YJ, Youn J.

Mol Cells. 2008 Feb 29;25(1):64-9.

7.

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.

Naugler WE, Karin M.

Trends Mol Med. 2008 Mar;14(3):109-19. doi: 10.1016/j.molmed.2007.12.007. Epub 2008 Feb 7. Review.

PMID:
18261959
8.

Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice.

Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, Le TV, Lorenz RG, Xu H, Kolls JK, Carter RH, Chaplin DD, Williams RW, Mountz JD.

Nat Immunol. 2008 Feb;9(2):166-75. Epub 2007 Dec 23.

PMID:
18157131
9.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
10.

The K/BxN mouse model of inflammatory arthritis: theory and practice.

Monach P, Hattori K, Huang H, Hyatt E, Morse J, Nguyen L, Ortiz-Lopez A, Wu HJ, Mathis D, Benoist C.

Methods Mol Med. 2007;136:269-82.

PMID:
17983155
11.

IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation.

Puccetti P, Grohmann U.

Nat Rev Immunol. 2007 Oct;7(10):817-23. Review.

PMID:
17767193
12.

Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.

Pertovaara M, Hasan T, Raitala A, Oja SS, Yli-Kerttula U, Korpela M, Hurme M.

Clin Exp Immunol. 2007 Nov;150(2):274-8. Epub 2007 Aug 17.

13.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

14.

Cytokines in the pathogenesis of rheumatoid arthritis.

McInnes IB, Schett G.

Nat Rev Immunol. 2007 Jun;7(6):429-42. Review.

PMID:
17525752
15.

Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice.

Szántó S, Koreny T, Mikecz K, Glant TT, Szekanecz Z, Varga J.

Arthritis Res Ther. 2007;9(3):R50.

16.

Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis.

Nguyen LT, Jacobs J, Mathis D, Benoist C.

Arthritis Rheum. 2007 Feb;56(2):509-20.

17.

The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation.

Kikly K, Liu L, Na S, Sedgwick JD.

Curr Opin Immunol. 2006 Dec;18(6):670-5. Epub 2006 Sep 28. Review. Erratum in: Curr Opin Immunol. 2007 Feb;19(1):111.

PMID:
17010592
18.

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

Muller AJ, Scherle PA.

Nat Rev Cancer. 2006 Aug;6(8):613-25. Review. Erratum in: Nat Rev Cancer. 2006 Sep;6(9):742.

PMID:
16862192
19.
20.

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P.

J Immunol. 2006 Jun 1;176(11):6752-61.

Supplemental Content

Support Center